Truist lowered the firm’s price target on Icon (ICLR) to $284 from $295 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s commentary at a recent healthcare investor conference around margins trends and expectations, reducing its FY25 EPS view to $14.70 from $15.18 and its FY25 adjusted EBITDA view to $1.79B from $1.84B, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.